For those participating in this 160-week period, patients received SAXENDA for a mean treatment duration of 110 weeks (median, 159 weeks)
doi: 10.12890/2020_001646 53 PolonikovA
Moreover, with pharmaceutical companies investing in production and clinical trials, the European market for GLP-1 is set to grow further in the coming years
Strengths Strictly FDA-approved medications Genuine specialist oversight Strong insurance navigation Coaching included Trade-offs Without coverage, brand-name medication is expensive No labs, wearables, or supplements bundled in Less flexible on dosing than a custom protocol Ro Body Program Ro is the option for clients who want a large, polished telehealth experience with broad availability
The TRIUMPH-1 trial, which focuses on core obesity management, is expected to read out in mid-2026
GOLD, 2023 Global Initiative for Chronic Obstructive Lung Disease (GOLD)